It is taking aim at some of the most difficult diseases, including lung cancer and diabetes. One promising candidate is atomoxetine, a new nonstimulant drug for attention-deficit disorder. Another potential winner is Cialis, an anti-impotence pill licensed from ICOS, a biotech upstart, that may have fewer side effects than Viagra. Both could hit the market next year. Taurel's biggest reason for optimism stems from a new breakthrough drug for a deadly blood disorder called sepsis.
Sepsis is among the leading causes of death in intensive care units.
Last month Lilly published trial results indicating that the drug is a lifesaver. Early this year Lilly sent to regulators its new drug application for Zovant. If all goes well, Zovant could win approval in late July just before Prozac's patent protection ends. Last month the final results of the trial were published. Taurel will need more than Zovant to replace the riches of Prozac.